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Background: Monoclonal antibodies (mAb), such as trastuzumab are a valuable addition to breast cancer therapy.
Data obtained from neoadjuvant settings revealed that antibody-dependent cell-mediated cytotoxicity (ADCC) is a
major mechanism of action for the mAb trastuzumab. Conflicting results still call into question whether disease
progression, prolonged treatment or concomitant chemotherapy influences ADCC and related immunological
phenomena.
Methods: We analyzed the activity of ADCC and antibody-dependent cell-mediated phagocytosis (ADCP) of
peripheral blood mononuclear cells (PBMCs) from human epidermal growth factor receptor 2 (HER2/neu) positive
breast cancer patients receiving trastuzumab therapy either in an adjuvant (n = 13) or metastatic (n = 15) setting as
well as from trastuzumab treatment-naive (t-naive) HER2/neu negative patients (n = 15). PBMCs from healthy volunteers
(n = 24) were used as controls. ADCC and ADCP activity was correlated with the expression of antibody binding
Fc-gamma receptor (FcγR)I (CD64), FcγRII (CD32) and FcγRIII (CD16) on CD14+ (monocytes) and CD56+ (NK) cells, as
well as the expression of CD107a+ (LAMP-1) on CD56+ cells and the total amount of CD4+CD25+FOXP3+ (Treg) cells. In
metastatic patients, markers were correlated with progression-free survival (PFS).
Results: ADCC activity was significantly down regulated in metastatic, adjuvant and t-naive patient cohorts as com-
pared to healthy controls. Reduced ADCC activity was inversely correlated with the expression of CD107a on CD56+
cells in adjuvant patients. ADCC and ADCP activity of the patient cohorts were similar, regardless of treatment duration
or additional chemotherapy. PFS in metastatic patients inversely correlated with the number of peripheral Treg cells.
Conclusion: The reduction of ADCC in patients as compared to healthy controls calls for adjuvant strategies, such as
immune-enhancing agents, to improve the activity of trastuzumab. However, efficacy of trastuzumab-specific ADCC
and ADCP appears not to be affected by treatment duration, disease progression or concomitant chemotherapy. This
finding supports the application of trastuzumab at any stage of the disease.
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Immunotherapy based on monoclonal antibodies (mAb)
targeting tumor-associated antigens (TAA) such as tras-
tuzumab (anti-human epidermal growth factor receptor
2; HER2/neu) is clinically effective [1-6] and has thus
become the standard of care for women with HER2/neu
expressing breast cancer [7-9]. However, when adminis-
tered as a monotherapy, this drug only yields response
rates of 12% to 35% [10-12]. Understanding the key mech-
anisms, which underlie the therapeutic efficacy of trastu-
zumab would enable oncologists to exclude patients from
therapy who probably do not benefit, and might also help
to assist in the development of adjuvant therapies that
enhance the therapeutic effects of this antibody.
It has been postulated that trastuzumabs’ anti-tumor
activity depends on multiple direct or indirect cytostatic
and/or cytotoxic effects [13-17]. Direct binding can in-
duce HER2/neu down regulation and the alteration of
several HER2/neu dependent cellular signaling pathways
leading to tumor growth inhibition. However, loss of
HER2/neu expression [18,19] and cell signal transduc-
tion inhibition was not necessarily relevant for the devel-
opment of resistance to trastuzumab in vivo and in a
nude mouse model [20,21].
Studies on animal models revealed that the therapeutic
activity of trastuzumab critically depends on the involve-
ment of Fc-gamma receptor (FcγR)-expressing lympho-
cytes [22,23]. With respect to FcγRI (CD64) and FcγRIII
(CD16) it could be demonstrated that mice lacking those
two receptors were unable to mount protective immune
responses against a virus-encoded tumor-specific antigen
[24]. These studies indicate that antibody-dependent cell-
mediated cytotoxicity (ADCC) is a major mechanism of
action for mAb. Moreover, trastuzumab present in breast
cancer patients’ serum after neoadjuvant application sig-
nificantly enhanced their ADCC activity [25,26]. It is im-
portant to note that ADCC correlated with therapeutic
response in that limited number of patients. In a meta-
static setting the correlation of ADCC and therapeutic
success is less clear. Some authors found that higher
ADCC was predictive of the lack of disease progression
[27], while other pilot studies did not observe a significant
association [28,29]. Due to contradictory results, ADCC is
currently regarded to be insufficient for the treatment of
metastatic cancer [30]. This would imply that different
mechanisms of trastuzumab, which are able to induce cell
death, are relevant at the later stages of the disease. Thus,
we concluded that more clinical data is required to gain
better understanding if disease progression and prolonged
treatment affects ADCC and its related immune para-
meters, which could then allow a functional design for
immune enhancing strategies and their proper applications.
Therefore, we investigated the impact of disease status,
adjuvant or metastatic, on ADCC and antibody-dependentcell-mediated phagocytosis (ADCP) in HER2/neu breast
cancer patients receiving trastuzumab. We also included
trastuzumab treatment-naive (t-naive) patients, which
were HER2/neu negative. Recently, a three-color flow
cytometric method has been developed to evaluate simul-
taneously ADCC and ADCP [31]. This technique has been
further adapted for trastuzumab and HER2/neu overex-
pressing cancer cells [32]. Using this method, we analyzed
the reactivity of peripheral blood mononuclear cells
(PBMCs) of adjuvant, metastatic and t-naive patients. Fur-
ther, we correlated this reactivity with the expression of
Fc-gamma receptors and the amount of regulatory T
(Treg) cells as a surrogate parameter for tumor-associated
immunosuppression.
Materials and methods
Study collective
15 metastatic and 13 adjuvant HER2/neu breast cancer
patients were enrolled in the study. All received trastu-
zumab, starting with a loading dose of 8 mg/kg, followed
by 6 mg/kg in a standard 3 week cycle. 15 HER2/neu
negative breast cancer patients served as a trastuzumab
treatment-naive (t-naive) group (patient characteristics
are shown in Table 1). Adjuvant patients received trastu-
zumab treatment for 1 year, whereas metastatic patients
were treated with trastuzumab until intolerable toxic-
ities, disease progression and switch to lapatinib or death
occurred. Blood samples were taken prior to a new trastu-
zumab application. Patients did neither receive radiother-
apy nor underwent any surgical intervention for at least
4 weeks prior to blood sampling. 24 healthy volunteers
served as a control group for the patient collective. Clin-
ical responses were determined according to response
evaluation criteria in solid tumors (RECIST). Progression-
free survival (PFS) was assessed in a 1-year follow-up.
Cell line
The human breast adenocarcinoma cell line SKBR3
(ATCC, Manasses, VA, USA) was grown in RPMI 1640
medium with 2 mM stable l-glutamine (PAA Labora-
tories, Pasching, Austria) and an addition of 10% heat
inactivated fetal calf serum (FCS; Linaris, Wertheim-
Bettingen, Germany). SKBR3 cells served as target (T)
cells in the ADCC/ADCP assay.
Isolation of PBMCs
Peripheral blood was drawn into ethylene diamine tetra-
acetic acid (EDTA) tubes (Greiner Bio-One, Kremsmün-
ster, Austria) and processed at room temperature (RT).
PBMCs were isolated by Ficoll-Paque (Amersham Pharma-
cia Biotech, Uppsala, Sweden) gradient centrifugation. One
aliquot of the PBMCs was resuspended in RPMI 1640
medium with 2 mM stable glutamine (PAA Laboratories)
containing 25% FCS (Linaris) and 5% dimethyl sulfoxide
Table 1 Clinical characteristics of participants
Healthy Adjuvant Metastatic T-Naive
Number, N 28 13 15 15
Age, years
Median 30 58 68 64
Range 23-55 37-82 40-75 34-74
HER2/neu receptor, N (%)
Positive N.A. 13 (100%) 15 (100%) 0 (0%)
Negative 0 (0%) 0 (0%) 15 (100%)
Estrogen receptor, N (%)
Positive N.A. 9 (69%) 8 (44%) 11 (70%)
Negative 4 (31%) 7 (46%) 4 (30%)
Progesterone receptor, N (%)
Positive N.A. 5 (38%) 1 (10%) 7 (40%)
Negative 8 (62%) 14 (90%) 8 (60%)
Trastuzumab, N N.A. 13 (100%) 15 (100%) N.A.
Median application
time, months
7 58
IQR 5 45
Chemotherapy, N (%)
FEC N.A. 1 (10%) 1 (10%)
FEC-Doc 1 (10%)
EC 3 (20%)
EC-D 2 (10%)
CMF 1 (10%)
Docetaxel + Epirubicin 3 (20%) 1 (10%)
Docetaxel 1 (10%)
Vinorelbin 1 (10%) 1 (10%)
Carboplatin 1 (10%)
Paclitaxel 1 (10%)
N: number of individuals; N.A.: not applicable; IQR: Interquartile range; FEC:
5-Fluorouracil, Epirubicin and Cyclophosphamide; FEC-Doc: 5-Fluorouracil,
Epirubicin, Cyclophosphamide and Docetaxel; EC: Epirubicin and
Cyclophosphamide; EC-D: Epirubicin, Cyclophosphamide and Docetaxel; CMF:
Cyclophosphamide, Methotrexate and 5-Fluorouracil.
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an intermediate cooling over night at −80°C, and stored
afterwards in liquid nitrogen for later marker analysis. he
rest of the freshly isolated PBMCs was used as effector (E)
cells in the ADCC/ADCP assay.
ADCC and ADCP assay
ADCC/ADCP activity of PBMCs was measured in a
three-color flow cytometric assay [31,32]. This recently
established method is capable of providing data for
ADCC and ADCP performance simultaneously. SKBR3
cells (1 × 106) were incubated with 1 μl of 0.5 mM
carboxyfluorescein diacetate succinimidyl ester (CFSE;
Invitrogen, Eugene, OR, USA) in PBS for 10 min at 37°C.Cells were washed in ice cold SKBR3 medium and
returned to normal cell culture conditions 24 hours prior
to the assay. The following day effector cells were mixed
with target cells at an E/T ratio of 25:1 (12.5 × 106/ml
effector cells, 5 × 105/ml target cells; final volume: 400 μl)
and incubated with or without antibodies (trastuzumab,
rituximab; Roche, Basel, Switzerland) at a concentration of
2.5 μg/ml for 2.5 hours at 37°C in a humidified atmos-
phere of 5% CO2. Subsequently, effector cells were labeled
with CD45 PE (Immunotech, Beckman Coulter, Marseille,
France), and dead cells with 7-aminoactinomycin D (7-AAD;
eBioscience, San Diego, CA, USA) followed by a three-color
flow cytometric analysis, carried out on a Gallios™ device
(Beckman Coulter). CFSE & 7AAD double positive cells rep-
resented tumor target cells killed by ADCC, whereas CFSE
& CD45 double positive cells were defined as tumor cells
phagocytized by immune cells (ADCP). The amount of
ADCC/ADCP activity was compared between cancer pa-
tients and healthy volunteers. Moreover, ADCC/ADCP levels
of patients were correlated with different PBMC markers
and PFS.Flow cytometric analysis of PBMCs
For the evaluation of Treg cells, IntraPrep (Immunotech)
was used for fixation and permeabilization followed by
staining with anti-forkhead-box-protein 3 (FOXP3) PE
(eBioscience), anti-CD4 ECD (Immunotech) and anti-
CD25 FITC (BD Pharmingen, Franklin Lakes, NJ, USA)
antibodies. Natural killer (NK) cells were defined by anti-
CD56 FITC (Sigma Aldrich). Monocytes were labeled with
anti-CD14 FITC (BD Pharmingen). Expression of FcγRI
was achieved by staining with anti-CD64 PC5 (Immuno-
tech), FcγRII with anti-CD32 PE (Acris Antibodies GmbH,
Herford, Germany) and FcγRIII with anti-CD16 PE
(Immunotech). The lysosomal-associated membrane pro-
tein 1 (LAMP-1) expression was determined by anti-
CD107a FITC (BD Pharmingen). IgG1 (Mouse) FITC/PE,
IgG1 (Mouse) PC5 and IgG1 (Mouse) ECD (Immunotech)
antibodies served as isotype controls.Statistical analysis
Statistical analyses were based on non-parametric tests
and carried out with IBM SPSS Statistics 20.0.0 software
(SPSS Inc., Chicago, IL, USA). Differences between the 3
groups were established using the Mann–Whitney-U-
Test. Correlations between the measured parameters
were assessed using Spearman’s rank correlation coeffi-
cient. A receiver operating characteristic curve (ROC) was
conducted to estimate a cut-off value for PFS. Kaplan-
Meier curves were calculated to show PFS within the
period of the follow-up, and were compared with a Log-
Rank test. For all statistical tests a two-sided p-value
of ≤ 0.05 was considered significant.
p=0.003 
p=0.004 
Figure 2 Trastuzumab-mediated ADCP of healthy volunteers
and breast cancer patients. The extent of ADCP was determined
by flow cytometry and is shown in % of total tumor cell counts. An
E/T ratio of 25:1 was used. White boxplots represent healthy
volunteers, light grey adjuvant, grey metastatic and dark grey
trastuzumab naive (t-naive) breast cancer patients. The addition of
trastuzumab is indicated at the bottom (−/+).
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and third quartiles are shown as boxes, including the
median. The whiskers display 1.5 times the interquartile
range (IQR). Dots represent outliers between 1.5 and 3
times the IQR. Triangles symbolize extreme outliers
above 3 times the IQR.
Ethics statement
This study protocol was approved by the “Ethics Com-
mittee of the Medical University of Vienna” (#445/2010).
All patients and healthy volunteers gave consent after
obtaining written information.
Results
First, we determined the potential of HER2/neu antibody-
specific ADCC and ADCP in breast cancer patients.
HER2/neu-specific ADCC was significantly reduced in the
adjuvant (p = 0.02), metastatic (p = 0.002) and t-naive
group (p < 0.001), when compared to healthy controls
(Figure 1). Similar results were obtained with an E/T ratio
of 12.5:1 (Additional file 1: Figure S1). For trastuzumab
treatment-naive patients we observed lower baseline
ADCC activity compared to all other groups (p < 0.001).
Analyzing ADCP, we observed significant reduction
in the adjuvant group (p = 0.003) and t-naive group
(p = 0.004) compared to healthy controls. In metastatic
patients, a tendency towards reduced ADCP was ob-
served (Figure 2). Here it is notable that adjuvant
patients were treated with anti-HER2/neu antibodies
for a median time of 7 months (IQR = 5), while meta-
static patients were treated for 58 months (IQR = 45).
However, neither treatment duration nor chemotherapyp<0.001 
p<0.001 
p<0.001 
p<0.001 
p=0.002 
p=0.02 
Figure 1 Trastuzumab-mediated ADCC of healthy volunteers
and breast cancer patients. The extent of ADCC was determined
by flow cytometry and is shown in % of total tumor cell counts. An E/T
ratio of 25:1 was used. White boxplots represent healthy volunteers,
light grey adjuvant, grey metastatic and dark grey trastuzumab naive
(t-naive) breast cancer patients. The addition of trastuzumab is
indicated at the bottom (−/+).within the preceding 3 months had an effect on ADCC
(Figure 3A, C) or ADCP efficiency (Figure 3B, D). Simi-
lar results were obtained using an E/T ratio of 12.5:1
(Additional file 2: Figure S2).
As the main effector cells of antibody-mediated tumor
cell killing of PBMCs are monocytes (CD14+) and NK
cells (CD56+), we investigated the singular contributions
of these two immune cell populations on ADCC and
ADCP activity. NK cells triggered in the presence of
trastuzumab substantial and significant levels of ADCC
(p = 0.002) but not of ADCP, whereas the picture was
completely opposite for monocytes (Additional file 3:
Figure S3A, B). Monocytes achieved high levels of
phagocytosis (p = 0.001) but no significant cytotoxicity.
Concerning complement-dependent cytotoxicity (CDC),
a trend towards trastuzumab-mediated CDC of cancer
cells was observed (Additional file 4: Figure S4, Additional
file 5: Supplementary methods), but this effect was not
significant. This is in line with previous studies stating
that CDC is indeed induced, but is not a major mechan-
ism of action for trastuzumab, except in combination with
CDC-enhancing agents [33].
ADCC and ADCP are mediated by subpopulations of
CD56+ and CD14+ cells, respectively. Therefore, we de-
termined the expression of FcγRI (CD64), FcγRII (CD32)
and FcγRIII (CD16) on the above-mentioned subpopula-
tions in our patients. Expression of CD16 was signifi-
cantly increased in CD14+ cells of patients treated in a
metastatic or adjuvant setting as well as in the t-naive
group (p = 0.001, p = 0.003 and p = 0.003 respectively),
as compared to healthy controls (Figure 4A). In contrast,
CD56+ cells showed a decrease of CD16 in the adjuvant
A B
rs=-0.02
p=0.92
rs=-0.004
p=0.986
C D
Figure 3 Influence of treatment duration and chemotherapy applied in the last 3 months on trastuzumab-mediated ADCC/ADCP. The
extent of ADCC/ADCP was determined by flow cytometry and is shown in % of total tumor cell counts. An E/T ratio of 25:1 was used. White
boxplots represent baseline ADCC/ADCP without trastuzumab (−) and light grey stimulation with trastuzumab (+). Applied chemotherapy (CTx) is
indicated on the bottom. A, C) ADCC. B, D) ADCP.
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group (Figure 5A). The expression of CD32 on monocytes
showed differences between the study cohorts (Figure 4C).
However, on NK cells this receptor was hardly detectable
(Figure 5D). CD64 expression was consistent on CD14+
cells in all cohorts (Figure 4B), but almost undetectable on
CD56+ cell (Figure 5B). LAMP-1 (CD107a), a degranula-
tion marker indicating cytotoxic activation [34,35], was up
regulated in the adjuvant cohort (p = 0.034), as compared
to healthy controls (Figure 5C). The percentage of Treg
cells of all CD4+ cells was not significantly altered in any
of the groups (Figure 6).
Moreover, we evaluated whether there was a correl-
ation between HER2/neu-specific ADCC/ADCP activity
and any CD14+ or CD56+ subpopulation measured
above. Patients in the adjuvant setting showed negative
correlations between CD56+CD107a+ cells (Figure 7;
rs = −0.797) and ADCC. Similar results were obtained
at an E/T ratio of 12.5:1 (Additional file 6: Figure S6;
rs = −0.8). In healthy controls, metastatic and t-naive
patients there was no correlation between any investi-
gated marker on PBMCs and ADCC/ADCP activity.We analyzed the predictive value of the parameters
mentioned above for PFS in metastatic patients assessed
in a 1-year follow-up. For this purpose, ROC analysis
was applied to measure the prognostic power by the area
under the curve, and to determine a threshold for pre-
diction of PFS. This revealed that only the number of
Treg cells could significantly predict PFS (Figure 8A;
AUC = 0.970, p = 0.004). Moreover, taking the cut-off
value at 1.1% of Treg cells of the amount of CD4+ cells
resulted in a diagnostic sensitivity and specificity of 90%
and 80%, respectively. There was a significant difference
(p = 0.022) between the groups above and below this
value and permitted a hypothetical prediction of PFS
depicted by Kaplan-Meier curves (Figure 8B).
Discussion
In this study, we demonstrated that neither disease pro-
gression nor duration of antibody treatment or chemo-
therapy had an impact on ADCC in HER2/neu breast
cancer patients. This finding, that trastuzumab-mediated
ADCC levels were not influenced by the treatment dur-
ation, is in line with the recent PHARE trial, which
A 
B 
C 
p=0.003 
p=0.001 
p=0.003 
p<0.001 
p=0.016 
Figure 4 Frequency of CD16, CD32 and CD64 expression on
monocytes of healthy volunteers and breast cancer patients
determined by flow cytometry. A) Frequency of CD14+CD16+
cells of total CD14+ cells is given in %. B) Frequency of CD14+C64+
cells of total CD14+ cells is given in %. C) The frequency of CD32+ on
monocytes (identified using FSC and SSC) is given in %. Patient cohorts
are indicated at the bottom.
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treatment compared to 6 months of adjuvant treatment
[36]. Nonetheless ADCC was lower in breast cancer pa-
tients as compared to healthy controls. This is also the
first study indicating ADCP occurrence in this type of
patients during treatment. In contrast to the popular be-
lief that the immune mechanisms of antibody treatment
deteriorate in metastatic cancer [30], our data indicates
that trastuzumab stimulates ADCC in the metastatic
setting as effectively as in the adjuvant setting. This sup-
ports the current clinical concept that trastuzumab
treatment can be applied beyond disease progression
[37-39] and at the same time underlines the relevance
of ADCC as the major mechanism at any stage of the
disease.
Chemotherapy associated immunosuppression leading
to reduced levels of activated CD56+ cells in breast can-
cer [40] appears to play a minor role for trastuzumab-
dependent ADCC. This could be attributed to the fact
that chemotherapy regimens of breast cancer patients
frequently contain taxanes, which are known to stimu-
late the immune system [41].
Analyzing cell types that are relevant for antibody
therapy, we found that CD16 expression on CD56+ cells
was reduced in all patient cohorts. Previously, it had
been shown in an in vitro stimulated cell culture trial
that ADCC activity leads to a reduction of this cell type
[26]. Thus, we hypothesize that one reason for the reduc-
tion of these particular cells in patient samples may be
that ADCC had already occurred in patients. We favor
this hypothesis over the notion that CD56+CD16+ cells
are reduced in tumors due to immunosuppression, as we
did not see a difference between adjuvant and metastatic
patients, the latter being likely more affected by immuno-
suppression. Since we observed lower ADCC activity in all
patients as compared to healthy control subjects, we sug-
gest that treatment might potentially lead to an inhibition
of ADCC, in part due to a decrease in ADCP reactivity.
Thus, adjuvant immunotherapies need to be developed to
counteract this effect. Moreover, we did not see a cor-
relation between CD56+CD16+ cells and ADCC as ob-
served by others [26]. An explanation for this could be the
fact, that Varchetta et al. assessed ADCC prior to therapy
or early during therapy, whereas we determined immune
parameters after prolonged therapy.
We also found an up regulation of CD107a on CD56+
cells in the adjuvant patient cohort. CD107a up regula-
tion has also been shown to occur in vitro following
ADCC, as this protein is a parameter for degranulation
[34,35]. Thus, we again hypothesize that the modulation
of this receptor is an indication that ADCC had oc-
curred in vivo in those patients rather than representing
a therapy-independent up regulation. Thus, increased
CD107a expression could be interpreted as a sign for
A B
C D
p=0.034 
p=0.006 
p=0.013 
p=0.001 
Figure 5 Frequency of CD16, CD32, CD64 and CD107a expression on NK cells of healthy volunteers and breast cancer patients
determined by flow cytometry. A) The frequency of CD56+CD16+ cells of total CD56+ cells is given in %. B) Frequency of CD56+CD64+ cells
of total of CD56+ cells is given in %. C) Frequency of CD56+C107a+ cells of total CD56+ cells is given in %. D) The frequency of CD56+CD32+ of
total CD56+ cells using lymphocyte gate (defined by FSC and SSC) is given in %. Patient cohorts are indicated at the bottom.
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Figure 6 Frequency of CD4+CD25+FOXP3+ cells (Treg) of total
CD4+ cells of healthy volunteers and breast cancer patients.
The frequency of CD25+FOXP3+ cells of total CD4+ cells was
determined by flow cytometry and is given in %. Patient cohorts are
indicated at the bottom.
rs=-0.797
p=0.001
Figure 7 Correlation of trastuzumab-mediated ADCC with the
frequency of CD107a expression on NK cells of adjuvant patients.
The frequency of CD56+CD107a+ cells of total CD56+ cells were
correlated with ADCC (E/T ratio 25:1) using Spearman’s rank
correlation coefficient.
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A B
AUC=0.970
p=0.004 p=0.022
< 1.1%
> 1.1%
Figure 8 Correlation between the frequency of Treg cells and PFS in metastatic breast cancer patients. (A) ROC chart. The area under the
curve served for the analysis of potentially diagnostic Treg cells’ sensitivity and specificity to assess the predictive value of Treg cells on PFS. (B)
Kaplan Meier curves evaluating this possible Treg cut-off value within 12 months of follow-up.
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body administration.
Although we found less CD56+ cells expressing CD16
in treated patients, we found a higher frequency of
CD16 on CD14+ cells in patients as compared to healthy
controls. This showed that ADCP is not associated with
a down regulation of cells expressing CD16. An increase
of CD14+CD16+ cells might rather be a sign of activa-
tion, as this cell type is reported to be increased in pa-
tients with acute and chronic infections undergoing
hemodialysis [42]. Alternatively, an up regulation of this
cell type might be a sign of the malignant disease itself,
as intermediate monocytes including CD14+CD16+ cells
had been enhanced in tumor patients [43]. This is in line
with a study by Feng et al. who even associated an
increase of CD14+CD16+ cells with tumor size and
pathological staging [44]. Taking the up regulation of
CD16 and its affinity to trastuzumab Fc into consideration
remains speculative because we did not look at soluble
HER2/neu in our patients’ sera. It could be that trastuzu-
mab forms complexes with this soluble receptor and binds
more efficiently to patients’ monocytes that have up regu-
lated CD16. But as our assay was done with isolated
PBMCs, tumor cells and artificial addition of trastuzumab,
no patient serum is included. Therefore we could not
address this phenomenon in our experimental approach.
Furthermore, we analyzed the CD64 expression on
CD14+ and CD56+ cells, as this receptor has been docu-
mented as a direct potent trigger molecule for ADCC and
phagocytosis [45,46]. CD64 was constitutively expressed
on monocytes and not altered within any of the groups.
On CD56+ cells, CD64 expression was almost undetect-
able as they usually do not express this receptor.
Additionally, we investigated CD32 expression, a recep-
tor which is involved in phagocytosis. Recently, expressionof CD32 in metastatic melanoma has been correlated with
an impairment of tumor susceptibility to IgG-dependent
cellular response [47]. We did not detect any CD32 ex-
pression on our SKBR3 cell line (data not shown), con-
firming the lack of this receptor in other cancers [48].
Usually monocytes consistently express activating CD32,
while inhibitory CD32 is only poorly expressed [49,50],
which rather speaks for its role as an activating receptor
on those cells. In our study we found a high expression
of CD32 on monocytes. However, reduced expression
levels did not necessarily correlate with reduced phago-
cytic activity as monocytes of the t-naive group had an
almost normal CD32 expression level but reduced
phagocytic activity. We did not find CD32 expression
on NK cells, which supports the notion that CD32 is
primarily expressed on monocytes and is enriched dur-
ing phagocytosis [51]. Recently, a novel polymorphism
affecting the locus encoding human Fc receptors has
been reported that leads to inhibitory CD32 expression
on NK cells and has been shown to negatively regulate
IgG-induced NK cell activation [52]. Obviously, this
mechanism does not apply for our patients.
The initial goal of this study was to determine an im-
mune marker that correlates with ADCC or ADCP activ-
ity. Our findings showed negative correlations between
CD56+CD107a+ cells and ADCC in the adjuvant setting,
which could possibly be a sign of immune activation.
Thus, effective therapy might be restrained by chronic
stimulation of effector cells.
We are aware of the fact that the healthy volunteers
enrolled in our study were younger compared to the
investigated breast cancer patients. However, we did not
find any correlation between age and ADCC/ADCP
activity in patients or healthy volunteers. This is in line
with studies on CD56+ and CD14+ cells, reporting that
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or increases with age [53,54] and, although the per-cell
activity for cytotoxicity decreases or stays the same, the
amount of ADCC is maintained [53]. Therefore, we
hypothesize that age-dependent immune-hyporeactivity
does not have an impact on our findings.
It is important to note that in this study we used an
excess of antibodies in our ex vivo ADCC and ADCP
assay as had also been done by Varchetta et al. [26]. This
gave us the opportunity to focus on the cellular reactiv-
ity of the patients’ immune system.
Interestingly, peripheral Treg cells, which had been
demonstrated to be up regulated during disease progres-
sion [55], were not observed to be significantly higher
in metastatic patients compared to healthy volunteers,
adjuvant or t-naive patients in our study. Moreover, no
correlation between the number of Treg cells and ADCC
or ADCP activity could be observed. One reason might
be the fact that trastuzumab itself can lead to a reduc-
tion of Treg cells [56]. Whether or not this is an effect of
chronic immune stimulation by trastuzumab therapy as
discussed above remains to be elucidated. Despite a pos-
sible down regulation of Treg cells by trastuzumab, they
were negatively correlated with disease progression in
metastatic cancer patients. This effect could be even
more prominent in tumor tissue. This indicates that Treg
cells are of biological relevance within the metastatic pa-
tient cohort [57-60]. It should be noted that the number
of Treg cells in peripheral blood might not be representa-
tive of the number of Treg cells infiltrating into the
tumor or its surrounding tissue.
We are further aware that ADCC also correlates with
FcγR-polymorphisms on CD56+CD16+ lymphocytes
[26,61-63], but we did not address this point in the
present study. To which extent these polymorphisms
affect total immune-cell killing mediated by trastuzumab
remains unclear and should be further investigated.
Conclusion
We conclude from our study that trastuzumab-mediated
ADCC is reduced in breast cancer patients compared to
healthy volunteers but is not further down regulated by dis-
ease progression, chemotherapy or prolonged antibody appli-
cation. Furthermore, results of our work propose Treg cells
as a potential prognostic factor in metastatic breast cancer.
Additional files
Additional file 1: Figure S1. Trastuzumab-mediated ADCC of healthy
volunteers and breast cancer patients. The extent of ADCC was
determined by flow cytometry and is shown in % of total tumor cell
counts. An E/T ratio of 12.5:1 was used. White boxplots represent healthy
volunteers, light grey adjuvant, grey metastatic and dark grey
trastuzumab naive (t-naive) breast cancer patients. The addition of
trastuzumab is indicated at the bottom (−/+).Additional file 2: Figure S2. Influence of treatment duration and
chemotherapy applied in the last 3 months on trastuzumab-mediated
ADCC. The extent of ADCC was determined by flow cytometry and is
shown in % of total tumor cell counts. An E/T ratio of 12.5:1 was used.
White boxplots represent baseline ADCC without trastuzumab (−) and
light grey stimulation with trastuzumab (+). Applied chemotherapy (CTx) is
indicated on the bottom.
Additional file 3: Figure S3. Trastuzumab-mediated ADCC/ADCP of
purified NK cells and monocytes of healthy volunteers. The extent of
ADCC/ADCP was determined by flow cytometry and is shown in % of
total tumor cell counts. An E/T ratio of 25:1 was used. White boxplots
represent baseline ADCC/ADCP without trastuzumab (−) and light grey
stimulation with trastuzumab (+). Different cell populations are indicated
at the bottom. A) ADCC. B) ADCP.
Additional file 4: Figure S4. Trastuzumab-mediated CDC of healthy
volunteers. The extent of CDC was determined by flow cytometry and is
shown in % of total tumor cell counts. An amount of 25% human serum
was used. The addition of trastuzumab is indicated at the bottom (−/+).
Additional file 5: Supplementary methods.
Additional file 6: Figure S6. Correlation of trastuzumab-mediated
ADCC with the frequency of CD107a expression on NK cells of adjuvant
patients. The frequency of CD56+CD107a+ cells of total CD56+ cells were
correlated with ADCC (E/T ratio 12.5:1) using Spearman’s rank correlation
coefficient.
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